NCT06218628View on ClinicalTrials.gov

Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 5, 2024

Primary Completion Date

August 22, 2029

Study Completion Date

August 27, 2030

Conditions
Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia MyelofibrosisChronic Myelomonocytic LeukemiaPolycythemia VeraEssential Thrombocytosis
Interventions
DRUG

Talazoparib

pacritinib in combination with talazoparib

DRUG

pacritinib

pacritinib in combination with talazoparib

Trial Locations (1)

19111-2497

RECRUITING

Fox Chase Cancer Center - Philadelphia, Philadelphia

All Listed Sponsors
lead

Fox Chase Cancer Center

OTHER